Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acerâs pipeline includes three clinical-stage candidates: EDSIVO⢠(celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; ACER-001 (a fully taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); and osanetant for the treatment of induced Vasomotor Symptoms (iVMS) where Hormone Replacement Therapy (HRT) is likely contraindicated. Acerâs product candidates are believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. Source
No articles found.
We have specialized in dermatology, as your skin's health is our concern. We aim t...
We have specialized in dermatology, as your ski...
The company creates herbal tonics to balance and build bodies and minds. Torii Lab...
The company creates herbal tonics to balance an...
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel ...
Harpoon Therapeutics is a clinical-stage immuno...
Vericel is a leader in advanced therapies for the sports medicine and severe burn ...
Vericel is a leader in advanced therapies for t...
Join the National Investor Network and get the latest information with your interests in mind.